Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 4/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.63 |
| ▸ | TSHR | P16473 | 1/20 | 0.63 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19067683 | 0.85 | ALDH1A1 (0.63) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL1724016 | 0.82 | ALDH1A1 (0.46) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL187316 | 0.81 | ALDH1A1 (0.59) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL27191747 | 0.81 | MAPT (0.51) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL10049913 | 0.80 | NPC1 (0.54) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL20439944 | 0.79 | TSHR (0.43) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL560326 | 0.78 | RAB9A (0.51) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL1556355 | 0.78 | NPSR1 (0.42) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL3620210 | 0.78 | ALDH1A1 (0.42) | HPGDALDH1A1TSHRL3MBTL1KMT2A | |
| SCHEMBL27788399 | 0.78 | ALDH1A1 (0.50) | HPGDALDH1A1TSHRL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-09-26 | — | — | US | disclosed |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | SIGNALRX PHARMACEUTICALS, INC. (US) | 2023-09-19 | — | — | US | disclosed |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2022-03-17 | — | — | US | disclosed |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2021-06-01 | — | — | US | disclosed |
| EP-3538523-B1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2021-05-19 | — | — | EP | disclosed |
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2019-11-07 | — | — | US | disclosed |
| EP-3538523-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | Cancer Research Technology Limited (GB) | 2019-09-18 | — | — | EP | disclosed |
| WO-2018087527-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2018-05-17 | — | — | WO | disclosed |
| WO-2018051254-A1 | CYCLIC SUBSTITUTED-1,2,4-OXADIAZOLE COMPOUNDS AS IMMUNOMODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190336502-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | HPGD 1969/4885ALDH1A1 2172/4885TSHR 4548/4885 |
| US-11760762-B2 | Thienopyranones and furanopyranones as kinase, bromodomain, and checkpoint inhibitors | CDK1, CDKN1A, CDKL1 | HPGD 2967/4885ALDH1A1 3077/4885TSHR 2452/4885 |
| US-11766434-B2 | Pyrimidinone derivatives as CDC7 inhibitors | CDC7, CDK7, CDK17 | HPGD 1969/4885ALDH1A1 2172/4885TSHR 4548/4885 |
| US-20220079942-A1 | PYRIMIDINONE DERIVATIVES AS CDC7 INHIBITORS | CDC7, CDK7, CDK17 | HPGD 1969/4885ALDH1A1 2172/4885TSHR 4548/4885 |
| US-11020396-B2 | Pyrimidinone derivatives as Cdc7 inhibitors | CDC7, CDK7, CDK17 | HPGD 1969/4885ALDH1A1 2172/4885TSHR 4548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.